Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANPIONE: Canagliflozin in Japanese type 2 diabetes with microalbuminuria
jRCTs061180047Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of canagliflozin in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Longitudinal change in urinary albumin-to-creatinine ratio during intervention and Change in eGFR slope. Started Aug 2018; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCTs061180047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180047.